Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update GlobeNewswire November 04, 2025 – Update on WTX-124 Phase 1/1b clinical trial interim data and End of Phase 1 meeting with the U.S. Food & Drug Administration (FDA) is expected to be provided later in the fourth quarter of 2025 – – Update […]

REMINDER – Stella-Jones Will Hold a Conference Call to Discuss its Third Quarter Results GlobeNewswire November 04, 2025 MONTREAL, Nov. 04, 2025 (GLOBE NEWSWIRE) — Stella-Jones Inc. (TSX:SJ). Open to: Investors, analysts and all interested parties Date: Wednesday November 5, 2025 Time: 10:00 AM Eastern Standard Time (EST) Live Webcast: https://meetings.lumiconnect.com/400-700-172-835 Call: (+1) 800 990

Blue Gold Strengthens Leadership Team with Appointment of Chief Technology Officer to Deliver Digital Strategy and Create Ecosystem for World's First Global Gold-Backed Digital Currency Proven innovator and technology executive Nathan Dionne to advance Blue Gold's mission of building the world's first gold-backed digital currency ecosystem GlobeNewswire November 04, 2025 NEW YORK, NY, Nov. 04,

Kamada Announces First Patient Enrolled into an Investigator-Initiated Clinical Trial of CYTOGAM(R) to Prevent Cytomegalovirus in Kidney Transplantation Post Marketing Study to Evaluate the Role of CYTOGAM in the Reduction of Risk of Late CMV Disease Following the Conclusion of Standardly Prescribed Antiviral Treatment in High-Risk Kidney Transplant Recipients GlobeNewswire November 04, 2025 REHOVOT, Israel,

Attralus To Present Phase 1/2 Data on Its Pan Amyloid Depleter at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition GlobeNewswire November 04, 2025 Initial results of a Phase 1 / 2 open label study of AT-02, the company's lead pan-amyloid removal therapeutic candidate, in patients with AL amyloidosis will be presented

Trust Wallet Turns Users Into VIPs With New Premium Program, Powered by TWT GlobeNewswire November 04, 2025 Trust Premium turns everyday wallet actions into progress and utility, powered by Trust XPs and TWT. DUBAI, United Arab Emirates, Nov. 04, 2025 (GLOBE NEWSWIRE) — Trust Wallet, the world's leading self-custody Web3 wallet with over 210 million

AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update GlobeNewswire November 04, 2025 AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update Sharpened investment focus on high-value assets, including three Phase 2 active immunotherapy programs and small molecule programs targeting NLRP3, Tau and a-syn Cash resources of

Purespring to present three posters at the American Society of Nephrology Kidney Week 2025 GlobeNewswire November 04, 2025 New information to be presented on the study design and methodology of Purespring's Phase I/II trial of PS-002, an AAV-based therapy delivering the complement factor I to podocytes in patients with IgA nephropathy Patient and carer feedback

EDAP to Present at Jefferies Global Healthcare Conference in London GlobeNewswire November 04, 2025 EDAP to Present at Jefferies Global Healthcare Conference in London Company to Present and Host 1×1 Investor Meetings on Tuesday, November 18th, 2025 AUSTIN, Texas, November 4, 2025 — EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic

InspireMD Reports Third Quarter 2025 Financial Results Successful initial CGuard Prime U.S. commercial launch drives record quarterly revenue GlobeNewswire November 04, 2025 MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard(R) Prime carotid stent system for the prevention of stroke, today announced financial and operating